Braive

"One platform for the full mental health journey" — Screening, triage, communication, treatment programs, AI scribe, outcome measurement – all on one platform with proven clinical effect. Built to EU MDR Class IIa standard.

Where it wins

• EU MDR Class IIa certification across the entire treatment journey, including the AI Scribe (Braive Note), which supports diagnostic coding and treatment recommendations beyond simple transcription [1].
• Proven clinical effect backed by published independent clinical research, addressing the crisis where 85% of people with mental health disorders never get help [1].
• Integrated guided iCBT programs, secure messaging, and video calls create a coherent experience for clinicians and patients, differentiating it from proliferating mental health apps [1].

Credibility: EU MDR Class IIa certification is a rigorous medical device standard; Braive Note is explicitly certified under this standard [1].

• Sells a comprehensive digital mental health platform that scales care delivery by combining clinical tools (screening, iCBT) with administrative efficiency (AI scribe) [1].
• Revenue scales with the number of organisations and clinicians using the platform, leveraging the EU MDR certification as a barrier to entry and trust signal [1].
• Margin likely sits in the software licensing and the AI Scribe module, which automates administrative tasks for clinicians [1].

• Braive differentiates from general mental health apps by offering EU MDR Class IIa certification and proven clinical effect [1].
• It competes with other digital therapy platforms by integrating AI scribe and outcome measurement into a single platform [1].
• Unlike simple telehealth tools, Braive provides a full journey from screening to treatment and monitoring [1].
• Differentiators: EU MDR certification, AI scribe with diagnostic coding, and published clinical research [1].

• 85% of people with mental health disorders never get help, indicating a massive access gap [1].
• Rising costs of the mental health crisis impacting individuals, healthcare organisations, and employers [1].
• Clinicians spending too much time on administration instead of patient care [1].
• Proliferation of mental health apps lacking clinical validation and integrated care journeys [1].

Braive's EU MDR certification is a significant moat, allowing it to target regulated healthcare markets where competitors cannot easily enter. The main risk is scaling while maintaining the high-touch support model that customers value. The opportunity lies in expanding into insurance and employer-sponsored health programs, as seen with Ageas. The next signal to watch is the adoption rate of the AI scribe, which could drive efficiency and stickiness.

Braive should consider developing a self-service onboarding path for smaller private practices to reduce sales dependency. The company could expand its clinical research partnerships to validate outcomes across more diverse patient populations. Developing a marketplace for third-party iCBT content could enhance the platform's value. Braive should also explore integrations with electronic health records (EHR) systems to streamline data flow for healthcare organisations.